RedHill Biopharma (RDHL) Shares Outstanding (Weighted Average) (2022 - 2024)
RedHill Biopharma (RDHL) has disclosed Shares Outstanding (Weighted Average) for 3 consecutive years, with $12.3 billion as the latest value for Q4 2024.
- Quarterly Shares Outstanding (Weighted Average) rose 57372.7% to $12.3 billion in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $12.3 billion through Dec 2024, up 57372.7% year-over-year, with the annual reading at $12.3 billion for FY2024, 57372.7% up from the prior year.
- Shares Outstanding (Weighted Average) for Q4 2024 was $12.3 billion at RedHill Biopharma, up from $21.4 million in the prior quarter.
- The five-year high for Shares Outstanding (Weighted Average) was $12.3 billion in Q4 2024, with the low at $21.4 million in Q4 2023.
- Average Shares Outstanding (Weighted Average) over 3 years is $4.3 billion, with a median of $616.3 million recorded in 2022.
- The sharpest move saw Shares Outstanding (Weighted Average) crashed 96.52% in 2023, then skyrocketed 57372.7% in 2024.
- Over 3 years, Shares Outstanding (Weighted Average) stood at $616.3 million in 2022, then plummeted by 96.52% to $21.4 million in 2023, then surged by 57372.7% to $12.3 billion in 2024.
- According to Business Quant data, Shares Outstanding (Weighted Average) over the past three periods came in at $12.3 billion, $21.4 million, and $616.3 million for Q4 2024, Q4 2023, and Q4 2022 respectively.